Evidence map›Paper›PMID 41979054›Full record

ArticleCPT: pharmacometrics & systems pharmacology2026

Objective First, Method Second: Why the Estimand Definition Comes First in Pharmacometric Covariate Modeling.

E Niclas Jonsson, Joakim Nyberg, France Mentré

Abstract read
In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

E Niclas JonssonPharmetheus AB, Uppsala, Sweden.ORCID https://orcid.org/0000-0002-2615-0280
Joakim NybergPharmetheus AB, Uppsala, Sweden.ORCID https://orcid.org/0000-0002-2839-4940
France MentréUniversité Paris Cité, Inserm, IAME, Paris, France.ORCID https://orcid.org/0000-0002-7045-1275

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pharmacometric covariate analyses support both mechanistic understanding and clinical decision-making, that is, two different objectives which require different analysis targets. Adopting the ICH E9(R1) estimand framework clarifies this distinction, reconciling mechanistic modeling (conditional covariate effects) with regulatory and clinical needs (unconditional covariate effects), clarifying that estimand definition, i.e. the objective, and not the estimator, is the first choice to make in covariate modeling. This structured approach optimizes quantitative evidence for communicating clinical impact and patient care.

Indexed as

Network PharmacologyModels, Biologicalcovariatesestimandmodel communicationpharmacometrics

Identifiers

PMID41979054
PMCPMC13274739

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.